Atlas Trials

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

Clinical trial NCT01873833 · TERMINATED

Trial details

NCT number
NCT01873833
Sponsor
University of Southern California
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Start date
2013-07-29
Primary completion
2021-03-02
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.